ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Prostate Related Issues
Testosterone therapy in prostate cancer
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 233235" data-attributes="member: 13851"><p><strong><u>KEY POINTS </u></strong></p><p><strong></strong></p><p><strong><em>*TTh in hypogonadal men is associated with a number of quality-of-life and clinical benefits </em></strong></p><p><strong><em></em></strong></p><p><strong><em>*Clinical use of TTh in hypogonadal men with a history of PCa was previously contraindicated based on a misunderstanding of the role serum T plays in androgen-driven growth activity in the prostate and remains controversial </em></strong></p><p><strong><em></em></strong></p><p><strong><em>*There is a plethora of data in support of the saturation model, which has redefined our understanding of how changes in serum testosterone influence local androgen activity in prostatic tissue </em></strong></p><p><strong><em></em></strong></p><p><strong><em>*Available literature examining the use of TTh in men with localized PCa following treatment with curative intent has displayed no increased risk of PCa progression or BCR in PCa in select groups of patients on TTh </em></strong></p><p></p><p><em><strong>*The potential benefits to an increasingly large group of patients along with the promising nature of preliminary data suggest an obligation for further evaluation of the risks and benefits in the form of clinical trials</strong></em></p></blockquote><p></p>
[QUOTE="madman, post: 233235, member: 13851"] [B][U]KEY POINTS [/U] [I]*TTh in hypogonadal men is associated with a number of quality-of-life and clinical benefits *Clinical use of TTh in hypogonadal men with a history of PCa was previously contraindicated based on a misunderstanding of the role serum T plays in androgen-driven growth activity in the prostate and remains controversial *There is a plethora of data in support of the saturation model, which has redefined our understanding of how changes in serum testosterone influence local androgen activity in prostatic tissue *Available literature examining the use of TTh in men with localized PCa following treatment with curative intent has displayed no increased risk of PCa progression or BCR in PCa in select groups of patients on TTh [/I][/B] [I][B]*The potential benefits to an increasingly large group of patients along with the promising nature of preliminary data suggest an obligation for further evaluation of the risks and benefits in the form of clinical trials[/B][/I] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Prostate Related Issues
Testosterone therapy in prostate cancer
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top